Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial

202487 citationsJournal Articlehybrid Open Access

Authors

AstraZeneca.

Good health and well-being

Published in: The Lancet Respiratory Medicine

Volume 13, Issue 1, pp. 59-68

Field-Weighted Citation Impact: 28.15